Request Info
Request Info

Fennec News

Fennec Pharmaceuticals Set to Join Russell 3000 Index

Research Triangle Park, NC, June 11, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced... Read More

Sign up for Updates